Hyperbilirubinemia is a common newborn condition. The purpose of this study was to examine the effect of ursodeoxycholic acid (UDCA) on infants with indirect hyperbilirubinemia. In neonates with indirect hyperbilirubinemia, ursodeoxycholic acid had additive effects with phototherapy. Ursodeoxycholic acid could be considered as a novel adjuvant therapy for neonatal indirect hyperbilirubinemia in order to decrease the mean total serum bilirubin and shorten the duration of phototherapy. Hyperbilirubinemia is a common newborn condition. The purpose of this study was to examine the effect of ursodeoxycholic acid (UDCA) on infants with indirect hyperbilirubinemia. In neonates with indirect hyperbilirubinemia, ursodeoxycholic acid had additive effects with phototherapy. Ursodeoxycholic acid could be considered as a novel adjuvant therapy for neonatal indirect hyperbilirubinemia in order to decrease the mean total serum bilirubin and shorten the duration of phototherapy.UDCA is considered an effective complementary therapeutic ad-  which renders this drug an excellent choice in neonatal indirect hy-  UDCA is considered an effective complementary therapeutic ad-  which renders this drug an excellent choice in neonatal indirect hy-  UDCA is considered an effective complementary therapeutic ad-  which renders this drug an excellent choice in neonatal indirect hy-  UDCA is considered an effective complementary therapeutic ad-  which renders this drug an excellent choice in neonatal indirect hy-  UDCA is considered an effective complementary therapeutic ad-  which renders this drug an excellent choice in neonatal indirect hy-  Hyperbilirubinemia is a common new-born condition. The purpose of this study was to examine the effect of ursodeoxycholic acid (UDCA) on infants with indirect hyperbilirubinemia. We have conducted a narrative review through electronic databases; PUBMED, EMBASE, for all relevant studies that were published up to 2022. In neonates with indirect hyperbilirubinemia, ursodeoxycholic acid had additive effects with phototherapy. Ursodeoxycholic acid could be considered as a novel adjuvant therapy for neonatal indirect hyperbilirubinemia in order to decrease the mean total serum bilirubin and shorten the duration of phototherapy.